Cellular Logistics has been awarded a $337,000 SBIR grant from the National Institutes of Health to further evaluate the functional immune and angiogenic (blood vessel growth) responses of the company’s Cardiac Fibroblast Matrix product, CFX™ Solus, for the treatment of early post-myocardial infarction, more commonly known as a heart attack.

“This exciting project will enhance our understanding of the cell-signaling mechanisms of how CFX™ Solus modulates the localized immune system and promotes the repair of damaged heart tissue”, says Alex Vodenlich, president, and chief executive officer.

CFX™ Solus, is a highly promising formulation of a regenerative medicine biomaterial designed to minimize injury and revitalize damaged heart tissue for patients suffering a heart attack. Suffering a heart attack can lead to a more serious condition, heart failure, which is a leading cause of death and hospitalization in the United States. Over six million Americans currently suffer from heart failure and this number is expected to exceed eight million by 2030.

Click here to read the full article.